Milestone Pharmaceuticals (NASDAQ:MIST) Rating Reiterated by HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $25.00 price target on the stock.

Separately, Piper Sandler reduced their price objective on Milestone Pharmaceuticals from $6.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, March 5th.

Milestone Pharmaceuticals Stock Performance

Shares of MIST stock traded up $0.01 during trading on Monday, reaching $1.33. 57,343 shares of the company’s stock were exchanged, compared to its average volume of 258,100. Milestone Pharmaceuticals has a twelve month low of $1.22 and a twelve month high of $3.86. The firm’s fifty day moving average price is $1.57 and its 200-day moving average price is $1.69. The company has a quick ratio of 22.75, a current ratio of 22.75 and a debt-to-equity ratio of 1.27. The stock has a market capitalization of $70.84 million, a PE ratio of -1.06 and a beta of 1.63.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.05. As a group, sell-side analysts anticipate that Milestone Pharmaceuticals will post -0.79 EPS for the current year.

Institutional Trading of Milestone Pharmaceuticals

An institutional investor recently raised its position in Milestone Pharmaceuticals stock. BNP Paribas Financial Markets lifted its stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 177.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,900 shares of the company’s stock after buying an additional 10,800 shares during the period. BNP Paribas Financial Markets’ holdings in Milestone Pharmaceuticals were worth $30,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.